FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Feasibility and safety of intrathecal transplantation of all...
Veterinary research communications2025; 49(6); 333; doi: 10.1007/s11259-025-10920-8

Feasibility and safety of intrathecal transplantation of allogeneic bone marrow mesenchymal stem cells in horses.

Abstract: Mesenchymal stem cells (MSCs) have emerged as a promising alternative for treating neurological disorders due to their neuroprotective, neuroregenerative, immunomodulatory, anti-inflammatory, and anti-apoptotic properties. The use of allogeneic MSCs offers advantages such as the selection of specific cells and their immediate availability. This study aimed to evaluate the safety and feasibility of intrathecal transplantation of allogeneic equine bone marrow-derived MSCs (EqBM-MSCs) in healthy horses. Ten healthy horses (five-12 years old) were randomly divided into two groups. In the control group (n = 5), phosphate-buffered saline was administered intrathecally, while the MSCs group (n = 5) received 3 × 10 allogeneic EqBM-MSCs. Safety and feasibility were assessed through physical examinations monthly for one year, cerebrospinal fluid (CSF) analysis before and six days after transplantation, and magnetic resonance imaging (MRI) one-year post-transplantation. No significant differences were found between the groups in physical examinations or CSF analysis before and six days after transplantation. Furthermore, MRI showed no changes after one year. Matrix Metalloproteinase-2 (MMP-2) expression was detected in the CSF before and after transplantation but showed no significant differences. These findings suggest that intrathecal transplantation of allogeneic EqBM-MSCs is safe and viable, offering a potential therapeutic approach for neurological disorders in horses.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Get Full Text
Publication Date: 2025-09-29 PubMed ID: 41021098PubMed Central: 4815220DOI: 10.1007/s11259-025-10920-8Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study investigated the safety and feasibility of injecting allogeneic bone marrow-derived mesenchymal stem cells (MSCs) into the spinal fluid of healthy horses.
  • The findings indicate that this type of stem cell transplantation is safe, with no adverse effects observed over a year-long follow-up, suggesting potential for treating neurological diseases in horses.

Background

  • Mesenchymal Stem Cells (MSCs): Multipotent cells capable of differentiating into various cell types.
  • Therapeutic Properties:
    • Neuroprotective – helping to protect nerve cells from damage
    • Neuroregenerative – aiding in the repair and regeneration of nervous tissue
    • Immunomodulatory – modifying immune system responses
    • Anti-inflammatory – reducing inflammation
    • Anti-apoptotic – preventing programmed cell death
  • Allogeneic MSCs: Cells sourced from a donor rather than the recipient, allowing immediate use and selection of specific cell populations.

Study Design

  • Subjects: Ten healthy horses, aged 5 to 12 years.
  • Groups:
    • Control group (n=5): received intrathecal injection of phosphate-buffered saline (placebo).
    • MSC group (n=5): received intrathecal injection of 3 × 10^7 allogeneic equine bone marrow-derived MSCs (EqBM-MSCs).
  • Intrathecal Injection: Injection into the cerebrospinal fluid (CSF) space surrounding the spinal cord.
  • Duration: One-year follow-up period.

Assessment Methods

  • Physical Examinations: Conducted monthly to monitor general health and detect any adverse effects.
  • Cerebrospinal Fluid (CSF) Analysis:
    • Baseline samples collected before transplantation.
    • Follow-up samples collected six days post-transplantation to assess changes in CSF composition and inflammation markers.
  • Magnetic Resonance Imaging (MRI): Performed one year post-transplantation to detect any structural changes or damage in the central nervous system.
  • Matrix Metalloproteinase-2 (MMP-2) Monitoring: MMP-2, a protein involved in tissue remodeling and inflammation, was measured in CSF to evaluate biochemical responses to transplantation.

Key Findings

  • Physical Health: No significant differences or adverse effects were observed between treated and control horses over the one-year period.
  • CSF Analysis:
    • No significant differences before and six days after transplantation between groups.
    • MMP-2 levels were present in all horses but did not differ significantly after transplantation, suggesting no increased inflammatory response.
  • MRI Results: No observable structural changes or damage noted in any horses one year post-transplantation.

Conclusions and Implications

  • Intrathecal transplantation of allogeneic EqBM-MSCs in healthy horses is safe and feasible with no detectable adverse effects.
  • This method provides a potential new treatment avenue for equine neurological disorders, given the stem cells’ regenerative and protective properties.
  • The study supports the practicality of using donor-derived MSCs, which can be prepared and administered promptly without the delay of autologous cell harvesting.
  • Further studies may be warranted to evaluate efficacy in horses affected by neurological diseases and to optimize dosing and administration protocols.

Cite This Article

APA
de Oliveira Ferreira LV, Maia L, Barberini DJ, Takahira RK, de Vasconcelos Machado VM, Machado GF, de Melo GD, Amorim RM. (2025). Feasibility and safety of intrathecal transplantation of allogeneic bone marrow mesenchymal stem cells in horses. Vet Res Commun, 49(6), 333. https://doi.org/10.1007/s11259-025-10920-8

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 49
Issue: 6
Pages: 333

Researcher Affiliations

de Oliveira Ferreira, Lucas Vinícius
  • Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
  • Center for Translational Research in Regenerative Medicine - Institute of Biotechnology, São Paulo State University, Botucatu, São Paulo, Brazil.
Maia, Leandro
  • Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Barberini, Danielle Jaqueta
  • Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Takahira, Regina Kiomi
  • Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
de Vasconcelos Machado, Vânia Maria
  • Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Machado, Gisele Fabrino
  • Department of Clinic, Surgery and Animal Reproduction, São Paulo State University (UNESP), Araçatuba, São Paulo, Brazil.
de Melo, Guilherme Dias
  • Department of Clinic, Surgery and Animal Reproduction, São Paulo State University (UNESP), Araçatuba, São Paulo, Brazil.
Amorim, Rogério Martins
  • Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil. rogerio.amorim@unesp.br.
  • Center for Translational Research in Regenerative Medicine - Institute of Biotechnology, São Paulo State University, Botucatu, São Paulo, Brazil. rogerio.amorim@unesp.br.

MeSH Terms

  • Animals
  • Horses
  • Mesenchymal Stem Cell Transplantation / veterinary
  • Mesenchymal Stem Cell Transplantation / adverse effects
  • Mesenchymal Stem Cell Transplantation / methods
  • Injections, Spinal / veterinary
  • Transplantation, Homologous / veterinary
  • Male
  • Mesenchymal Stem Cells
  • Female
  • Feasibility Studies
  • Magnetic Resonance Imaging / veterinary

Conflict of Interest Statement

Declarations. Consent for publication: Not applicable. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethics approval: All phases of this study were approval from the Ethics Committee on Animal Use of UNESP – Botucatu. According to protocol number 76/2009-CEUA. All procedures were carried out in accordance with international guidelines for the care and use of experimental animals. Consent to participate: Not applicable. Clinical trial number: Not applicable.

References

This article includes 52 references
  1. Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci 8:2002944.
    doi: 10.1002/advs.202002944google scholar: lookup
  2. Ardanaz N, Vázquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Martín-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints. BMC Vet Res 12:65.
    doi: 10.1186/s12917-016-0692-xpubmed: 27029614pmc: 4815220google scholar: lookup
  3. Bacelar RGA, Filho FCC, Costa JA, Costa APR, Nóbrega MMGP, Muratori MCS. Fusarium spp. and fumonisin in feed for equine and its importance for occurrence of leukoencephalomalacia. Afr J Microbiol Res 10:1248–1256.
    doi: 10.5897/AJMR2016.8204google scholar: lookup
  4. Barberini DJ, Aleman M, Aristizabal F, Spriet M, Clark KC, Walker NJ, Galuppo LD, Amorim RM, Woolard KD, Borjesson DL. Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses. Stem Cell Res Ther 9:96.
    doi: 10.1186/s13287-018-0849-6pubmed: 29631634pmc: 5891950google scholar: lookup
  5. Barmada A, Sharan J, Band N, Prodromos C. Serious adverse events have not been reported with spinal intrathecal injection of mesenchymal stem cells: a systematic review. Curr Stem Cell Res Ther 18:829–833.
    doi: 10.2174/1574888X17666220817125324pubmed: 35980065google scholar: lookup
  6. Bedenice D, Johnson AL. Neurologic conditions affecting the equine athlete. Vet Clin North Am Equine Pract 34:277–297.
    doi: 10.1016/j.cveq.2018.04.006pubmed: 30007448google scholar: lookup
  7. Benavides FP, Pinto GBA, Heckler MCT, Hurtado DMR, Teixeira LR, Monobe MMS, Machado GF, de Melo GD, Rodríguez-Sánchez DN, Alvarenga FDCLE, Amorim RM. Intrathecal transplantation of autologous and allogeneic bone Marrow-derived mesenchymal stem cells in dogs. Cell Transpl 30:9636897211034464.
    doi: 10.1177/09636897211034464google scholar: lookup
  8. Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Ther 8:288.
    doi: 10.1186/s13287-017-0742-8pubmed: 29273086pmc: 5741939google scholar: lookup
  9. Bergman RL, Inzana KD, Inzana TJ. Characterization of matrix metalloproteinase-2 and – 9 in cerebrospinal fluid of clinically normal dogs. Am J Vet Res 63:1359–1362.
    doi: 10.2460/ajvr.2002.63.1359pubmed: 12371760google scholar: lookup
  10. Burk J, Ribitsch I, Gittel C, Juelke H, Kasper C, Staszyk C, Brehm W. Growth and differentiation characteristics of equine mesenchymal stromal cells derived from different sources. Vet J 195:98–106.
    doi: 10.1016/j.tvjl.2012.06.004pubmed: 22841420google scholar: lookup
  11. Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials 76:371–87.
    doi: 10.1016/j.biomaterials.2015.10.065pubmed: 26561934google scholar: lookup
  12. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med 4:1–11.
    doi: 10.3727/215517912X647217pubmed: 23152950pmc: 3495591google scholar: lookup
  13. Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev 23:1258–1265.
    doi: 10.1089/scd.2013.0537pubmed: 24438346google scholar: lookup
  14. Chiaradia E, Miller I. In slow pace towards the proteome of equine body fluids. J Proteomics 225:103880.
    doi: 10.1016/j.jprot.2020.103880pubmed: 32569818google scholar: lookup
  15. Colpo GD, Furr Stimming E, Teixeira AL. Stem cells in animal models of huntington disease: a systematic review. Mol Cell Neurosci 95:43–50.
    doi: 10.1016/j.mcn.2019.01.006pubmed: 30685323google scholar: lookup
  16. Conrado FO, Beatty SSK. Fluid analysis in the equine patient: cerebrospinal, synovial, and peritoneal fluids. Vet Clin North Am Equine Pract .
    doi: 10.1016/j.cveq.2021.01.002pubmed: 33618950google scholar: lookup
  17. Cudna A, Bronisz E, Mirowska-Guzel D, Kurkowska-Jastrzębska I. Serum levels of matrix metalloproteinase 2 and its inhibitor after tonic-clonic seizures. Epilepsy Res 192:107115.
    doi: 10.1016/j.eplepsyres.2023.107115pubmed: 36958106google scholar: lookup
  18. Dimarakis I, Levicar N. Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells 24:1407–1408.
    doi: 10.1634/stemcells.2005-0577pubmed: 16456132google scholar: lookup
  19. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8:315–317.
    doi: 10.1080/14653240600855905pubmed: 16923606google scholar: lookup
  20. Durand N, Zubair AC. Autologous versus allogeneic mesenchymal stem cell therapy: the pros and cons. Surgery 171:1440–1442.
    doi: 10.1016/j.surg.2021.10.057pubmed: 34863523google scholar: lookup
  21. Furr M, Reed S. Examination of the nervous system. .
    doi: 10.1002/9781118993712google scholar: lookup
  22. Gugjoo MB, Amarpal Makhdoomi DM, Sharma GT. Equine mesenchymal stem cells: properties, sources, characterization, and potential therapeutic applications. J Equine Vet Sci 72:16–27.
    doi: 10.1016/j.jevs.2018.10.007pubmed: 30929778google scholar: lookup
  23. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, Miller-Podraza H, Blomqvist M, Olonen A, Salo H, Lehenkari P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 25:197–202.
    doi: 10.1634/stemcells.2006-0444pubmed: 17008421google scholar: lookup
  24. Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci 23:10023.
    doi: 10.3390/ijms231710023pubmed: 36077421pmc: 9456387google scholar: lookup
  25. Jaillard A, Hommel M, Moisan A, Zeffiro TA, Favre-Wiki IM, Barbieux-Guillot M, Vadot W, Marcel S, Lamalle L, Grand S, Detante O. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl Stroke Res 11:910–923.
    doi: 10.1007/s12975-020-00787-zpubmed: 32462427google scholar: lookup
  26. Kang X, Li Y, Wei J, Zhang Y, Bian C, Wang K, Wu X, Hu Y, Li J, Yang Y. Elevation of matrix metalloproteinase-9 level in cerebrospinal fluid of tick-borne encephalitis patients is associated with IgG extravassation and disease severity. PLoS ONE 8:e77427.
    doi: 10.1371/journal.pone.0077427pubmed: 24223711pmc: 3815297google scholar: lookup
  27. Kim H, Na DL, Lee NK, Kim AR, Lee S, Jang H. Intrathecal injection in a rat model: a potential route to deliver human wharton’s jelly-derived mesenchymal stem cells into the brain. Int J Mol Sci 21:1272.
    doi: 10.3390/ijms21041272google scholar: lookup
  28. Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. Alzheimers Res Ther 13:154.
    doi: 10.1186/s13195-021-00897-2pubmed: 34521461pmc: 8439008google scholar: lookup
  29. Kishk NA, Abokrysha NT, Gabr H. Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection. J Clin Neurosci 20:310–312.
    doi: 10.1016/j.jocn.2012.04.013pubmed: 23157845google scholar: lookup
  30. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 29:11–19.
    doi: 10.1002/stem.559pubmed: 21280155google scholar: lookup
  31. Kutasi O, Bakonyi T, Lecollinet S, Biksi I, Ferenczi E, Bahuon C, Sardi S, Zientara S, Szenci O. Equine encephalomyelitis outbreak caused by a genetic lineage 2 West nile virus in Hungary. J Vet Intern Med 25:586–591.
    doi: 10.1111/j.1939-1676.2011.0715.xpubmed: 21457323google scholar: lookup
  32. Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci 11:187.
    doi: 10.1186/s13578-021-00698-ypubmed: 34727974pmc: 8561357google scholar: lookup
  33. Maia L, Landim-Alvarenga FC, Da Mota LS, De Assis Golim M, Laufer-Amorim R, De Vita B, Barberini DJ, Listoni AJ, De Moraes CN, Heckler MC, Amorim RM. Immunophenotypic, immunocytochemistry, ultrastructural, and cytogenetic characterization of mesenchymal stem cells from equine bone marrow. Microsc Res Tech 76:618–624.
    doi: 10.1002/jemt.22208pubmed: 23533133google scholar: lookup
  34. Maia L, da Cruz Landim-Alvarenga F, Taffarel MO, de Moraes CN, Machado GF, Melo GD, Amorim RM. Feasibility and safety of intrathecal transplantation of autologous bone marrow mesenchymal stem cells in horses. BMC Vet Res 11:63.
    doi: 10.1186/s12917-015-0361-5pubmed: 25879519pmc: 4369105google scholar: lookup
  35. Mayhew IGJ, MacKay R. Physical, chemical, and thermal causes. .
    doi: 10.1002/9781119477204.ch33google scholar: lookup
  36. Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, Kim HJ, Ki CS, Kim SH. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol 84:361–373.
    doi: 10.1002/ana.25302pubmed: 30048006pmc: 6175096google scholar: lookup
  37. Pan K, Deng L, Chen P, Peng Q, Pan J, Wu Y, Wang Y. Safety and feasibility of repeated intrathecal allogeneic bone marrow-derived mesenchymal stromal cells in patients with neurological diseases. Stem Cells Int 2019:8421281.
    doi: 10.1155/2019/8421281pubmed: 31428161pmc: 6683773google scholar: lookup
  38. Paré J, Moore A. West Nile virus in horses—what do you need to know to diagnose the disease?. Can Vet J 59:1119–1120.
    pubmed: 30510321pmc: 6135266
  39. Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol 73:337–344.
    doi: 10.1001/jamaneurol.2015.4321pubmed: 26751635google scholar: lookup
  40. Rascón-Ramírez FJ, Esteban-García N, Barcia JA, Trondin A, Nombela C, Sánchez-Sánchez-Rojas L. Are we ready for cell therapy to treat stroke?. Front Cell Dev Biol 9:621645.
    doi: 10.3389/fcell.2021.621645pubmed: 34249901pmc: 8260969google scholar: lookup
  41. Sarsenova M, Kim Y, Raziyeva K, Kazybay B, Ogay V, Saparov A. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells. Front Immunol 13:1010399.
    doi: 10.3389/fimmu.2022.1010399pubmed: 36211399pmc: 9537745google scholar: lookup
  42. Shahror RA, Linares GR, Wang Y, Hsueh SC, Wu CC, Chuang DM, Chiang YH, Chen KY. Transplantation of mesenchymal stem cells overexpressing fibroblast growth factor 21 facilitates cognitive recovery and enhances neurogenesis in a mouse model of traumatic brain injury. J Neurotrauma 37:14–26.
    doi: 10.1089/neu.2019.6422pubmed: 31298621google scholar: lookup
  43. Soares MBP, Gonçalves RGJ, Vasques JF, da Silva-Junior AJ, Gubert F, Santos GC, de Santana TA, Almeida Sampaio GL, Silva DN, Dominici M, Mendez-Otero R. Current status of mesenchymal stem/stromal cells for treatment of neurological diseases. Front Mol Neurosci 15:883378.
    doi: 10.3389/fnmol.2022.883378pubmed: 35782379pmc: 9244712google scholar: lookup
  44. Sun Z, Gu P, Xu H, Zhao W, Zhou Y, Zhou L, Zhang Z, Wang W, Han R, Chai X, An S. Human umbilical cord mesenchymal stem cells improve locomotor function in parkinson’s disease mouse model through regulating intestinal microorganisms. Front Cell Dev Biol 9:808905.
    doi: 10.3389/fcell.2021.808905pubmed: 35127723pmc: 8810651google scholar: lookup
  45. Timaner M, Tsai KK, Shaked Y. The multifaceted role of mesenchymal stem cells in cancer. Semin Cancer Biol 60:225–237.
    doi: 10.1016/j.semcancer.2019.06.003pubmed: 31212021google scholar: lookup
  46. Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS. Mesenchymal stem cells for multiple sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials 20:263.
    doi: 10.1186/s13063-019-3346-zpubmed: 31072380pmc: 6507027google scholar: lookup
  47. Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem 139:91–114.
    doi: 10.1111/jnc.13415pubmed: 26525923google scholar: lookup
  48. Yang Y, Pang M, Du C, Liu ZY, Chen ZH, Wang NX, Zhang LM, Chen YY, Mo J, Dong JW, Xie PG, Wang QY, Liu B, Rong LM. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy 23:57–64.
    doi: 10.1016/j.jcyt.2020.09.012pubmed: 33218835google scholar: lookup
  49. Yao P, Zhou L, Zhu L, Zhou B, Yu Q. Mesenchymal stem cells: a potential therapeutic strategy for neurodegenerative diseases. Eur Neurol 83:235–241.
    doi: 10.1159/000509268pubmed: 32690856google scholar: lookup
  50. Zhang J, Huang X, Wang H, Liu X, Zhang T, Wang Y, Hu D. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther 6:234.
    doi: 10.1186/s13287-015-0240-9pubmed: 26620426pmc: 4665863google scholar: lookup
  51. Zhang HL, Xie XF, Xiong YQ, Liu SM, Hu GZ, Cao WF, Wu XM. Comparisons of the therapeutic effects of three different routes of bone marrow mesenchymal stem cell transplantation in cerebral ischemic rats. Brain Res 1680:143–154.
    doi: 10.1016/j.brainres.2017.12.017pubmed: 29274877google scholar: lookup
  52. Zhang YT, He KJ, Zhang JB, Ma QH, Wang F, Liu CF. Advances in intranasal application of stem cells in the treatment of central nervous system diseases. Stem Cell Res Ther 12:210.
    doi: 10.1186/s13287-021-02274-0pubmed: 33762014pmc: 7992869google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,002 horse owners like you who receive our email updates on horse health and nutrition.